Episode Details

Benitec Biopharma Inc. (BNTC) FY2026 — Reference quote $12.08 at September 14 close; no clean post-release reaction quote captured. Benitec has $180 million cash, but prefunded warrants change what each share owns. Equity compensation and uncertain clinical economics drive the valuation. THE CALL: SELL (3/5, MODERATE) — September 2027 twelve-month target ~$6.62 vs ~$12.08 at the September 14, 2026 release-boundary close. KEY METRICS: - FY2026 net loss $45.546M; operating expense $51.192M - Cash equivalents $179.972M at June 30 - SBC $26.410M; OCF cash use $16.518M - Economic shares 49.487M including prefunded warrants; computed cash/share $3.64 - 12-month target $6.62; probability-weighted scenario value $7.702; Very High uncertainty What to watch: Clear pivotal requirements, durable follow-up, a reconciled economic cap table and no renewed material compensation-accounting corrections. Full research packet: https://chargedalpha.com/research/bntc-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.